Autotaxin inhibitors: A perspective on initial medicinal chemistry efforts
Abstract
The lysophospholipase D enzyme, autotaxin (ATX), has been linked to numerous human diseases including cancer, neurophatic pain, obesity and Alzheimer's disease. Although the ATX protein was initially purified and characterized in 1992, a link to bioactive lipid metabolism was not made until 2002. In the past decade, metal chelators, lysophospholipid product analogs, and more recently, small non-lipid inhibitors of the enzyme were successfully identified. The majority of these inhibitors have been characterized using recombinant purified ATX in vitro, with very few examples studied in more complex systems. Translation of ATX inhibitors from the hands of medicinal chemists to clinical use will require substantially expanded characterization of ATX inhibitors in vivo. © 2010 Informa UK, Ltd.
Publication Title
Expert Opinion on Therapeutic Patents
Recommended Citation
Parrill, A., & Baker, D. (2010). Autotaxin inhibitors: A perspective on initial medicinal chemistry efforts. Expert Opinion on Therapeutic Patents, 20 (12), 1619-1625. https://doi.org/10.1517/13543776.2010.533658
